Clinical and laboratory assessments were made for all enrolled patients at both baseline and follow-up visits. Patients’ medical history was recorded with a short questionnaire. Anthropometric measurements such as body weight, body height, body mass index (BMI), waist circumference, systolic and diastolic blood pressure were recorded. Hypertension and diabetes mellitus was recorded based on self-reported medical history. Dyslipidemia and central obesity (base on waist circumference, for females, ≥80 cm; for males, ≥90 cm) were defined as previously reported [20 (link)]. The ULN of ALT was 40 U/L [14 ]. Serum HBsAg and HBV DNA levels were detected by Elecsys HBsAg II assays (detection limit: 0.05 IU/mL; Roche Diagnostics Gmbh, Mannheim, Germany), and Cobas TaqMan assay kit (detection limit: 20 IU/mL; Roche Diagnostics, Branchburg, NJ), respectively.
Cobas taqman assay kit
Manufactured by Roche
Sourced in Germany, United States
The Cobas TaqMan assay kit is a laboratory equipment product developed by Roche. The core function of this kit is to enable the detection and quantification of specific nucleic acid sequences through real-time PCR (polymerase chain reaction) technology. The kit provides the necessary reagents and protocols to perform quantitative nucleic acid analysis in a laboratory setting.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using cobas taqman assay kit
1
Comprehensive Clinical Assessment of Chronic Hepatitis B
2
Quantitative Hepatitis B Biomarkers
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum ALT levels were assessed according to standard procedures (Olympus AU5400, Olympus Corporation, Tokyo, Japan), and the upper limit of normal (ULN) ALT was defined as 50 IU/L for men and 38 IU/L for women. Serum HBsAg concentration was quantitatively assessed using Elecsys® HBsAg II Quant Assay (Roche Diagnostics, Penzberg, Germany), with a dynamic range of 20 to 52,000 IU/mL. If qHBsAg levels >52,000 IU/mL, samples were retested with a stepwise dilution of 1:4000. Serum hepatitis B e antigen (HBeAg) was determined by the electrochemiluminescence immunoassay (Roche Diagnostics, Indianapolis, IN, USA). Serum concentrations of HBV-DNA were determined using Cobas Taqman assay kit (Roche Diagnostics, Branchburg, NJ), with a lower limit of detection of 20 IU/mL. HBV genotypes were determined by direct S-gene sequencing.
3
Quantitative HBV Biomarker Profiling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum biochemical indexes were measured according to standard procedures (Olympus AU5400, Olympus Corporation, Tokyo, Japan). Serum HBsAg levels were quantitatively measured using an Elecsys® HBsAg II Quant Assay (Roche Diagnostics, Penzberg, Germany). Serum HBeAg status was assessed using electrochemiluminescence immunoassay (Roche Diagnostics, Indianapolis, IN, United States). Serum HBV DNA concentration was quantitatively determined using a Cobas TaqMan assay kit (Roche Diagnostics, Branchburg, NJ, United States), with a lower limit of detection of 20 IU/mL.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!